Literature DB >> 16917105

Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

Valerie Y Ng1, Christophe Morisseau, John R Falck, Bruce D Hammock, Deanna L Kroetz.   

Abstract

OBJECTIVE: Proliferation of smooth muscle cells is implicated in cardiovascular complications. Previously, a urea-based soluble epoxide hydrolase inhibitor was shown to attenuate smooth muscle cell proliferation. We examined the possibility that urea-based alkanoic acids activate the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) and the role of PPARalpha in smooth muscle cell proliferation. METHODS AND
RESULTS: Alkanoic acids transactivated PPARalpha, induced binding of PPARalpha to its response element, and significantly induced the expression of PPARalpha-responsive genes, showing their function as PPARalpha agonists. Furthermore, the alkanoic acids attenuated platelet-derived growth factor-induced smooth muscle cell proliferation via repression of cyclin D1 expression. Using small interfering RNA to decrease endogenous PPARalpha expression, it was determined that PPARalpha was partially involved in the cyclin D1 repression. The antiproliferative effects of alkanoic acids may also be attributed to their inhibitory effects on soluble epoxide hydrolase, because epoxyeicosatrienoic acids alone inhibited smooth muscle cell proliferation.
CONCLUSIONS: These results show that attenuation of smooth muscle cell proliferation by urea-based alkanoic acids is mediated, in part, by the activation of PPARalpha. These acids may be useful for designing therapeutics to treat diseases characterized by excessive smooth muscle cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917105      PMCID: PMC1904341          DOI: 10.1161/01.ATV.0000242013.29441.81

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

Review 1.  Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery.

Authors:  V Sriram; C Patterson
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

2.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

Review 3.  Proteins interacting with the mammalian estrogen receptor: proposal for an integrated model for estrogen receptor mediated regulation of transcription.

Authors:  A P Govind; R V Thampan
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

Review 4.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

5.  Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia.

Authors:  S Narravula; S P Colgan
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.

Authors:  F Yin; S Wakino; Z Liu; S Kim; W A Hsueh; A R Collins; A J Van Herle; R E Law
Journal:  Biochem Biophys Res Commun       Date:  2001-09-07       Impact factor: 3.575

7.  Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells.

Authors:  B Yang; L Graham; S Dikalov; R P Mason; J R Falck; J K Liao; D C Zeldin
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

Review 8.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

9.  Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.

Authors:  P Cronet; J F Petersen; R Folmer; N Blomberg; K Sjöblom; U Karlsson; E L Lindstedt; K Bamberg
Journal:  Structure       Date:  2001-08       Impact factor: 5.006

10.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.

Authors:  D Resnitzky; M Gossen; H Bujard; S I Reed
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

View more
  10 in total

Review 1.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

Review 2.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 3.  Arachidonic acid cytochrome P450 epoxygenase pathway.

Authors:  Arthur A Spector
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

4.  Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.

Authors:  Jun-Yan Liu; Jun Yang; Bora Inceoglu; Hong Qiu; Arzu Ulu; Sung-Hee Hwang; Nipavan Chiamvimonvat; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2009-11-05       Impact factor: 5.858

5.  Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.

Authors:  Alexis N Simpkins; R Daniel Rudic; Derek A Schreihofer; Sid Roy; Marlina Manhiani; Hsing-Ju Tsai; Bruce D Hammock; John D Imig
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

6.  Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model.

Authors:  Christi M Terry; Mary L Carlson; Yuxia He; Arzu Ulu; Christophe Morisseau; Donald K Blumenthal; Bruce D Hammock; Alfred K Cheung
Journal:  J Vasc Res       Date:  2014-09-05       Impact factor: 1.934

Review 7.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

8.  Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.

Authors:  Jun-Yan Liu; Hsing-Ju Tsai; Sung Hee Hwang; Paul D Jones; Christophe Morisseau; Bruce D Hammock
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

9.  Soluble epoxide hydrolase inhibition modulates vascular remodeling.

Authors:  A N Simpkins; R D Rudic; S Roy; H J Tsai; B D Hammock; J D Imig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-24       Impact factor: 4.733

10.  Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.

Authors:  Hyo Seon Kim; Sang Kyum Kim; Keon Wook Kang
Journal:  Int J Mol Sci       Date:  2017-12-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.